Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs

Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY).

(2021) Changhoon Yoo et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunological and Toxicological Considerations for the Design of Liposomes

(2020) Collin T. Inglut et al.   Nanomaterials

Differentiation of liposomal irinotecan from dose-dense non-liposomal irinotecan in patient-derived pancreatic cancer xenograft tumor models.

(2020) Sandrine Barbier et al.   JOURNAL OF CLINICAL ONCOLOGY

First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer

(2020) Hossein Taghizadeh et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis

(2020) Xiaoyun Zhu et al.   BIOSCIENCE REPORTS

Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1

(2020) Li-Tzong Chen et al.   PANCREATOLOGY

nal‐IRI+5‐FU/LV versus 5‐FU/LV in post‐gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients

(2020) Makoto Ueno et al.   Cancer Medicine

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase

(2020) Jasgit C. Sachdev et al.   BREAST CANCER RESEARCH AND TREATMENT

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study

(2019) L. Perkhofer et al.   BMC CANCER

Comparison of effects of UGT1A1*6 and UGT1A1*28 on irinotecan-induced adverse reactions in the Japanese population: analysis of the Biobank Japan Project

(2019) Keiko Hikino et al.   JOURNAL OF HUMAN GENETICS

Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients

(2018) E. Palmerini et al.   ACTA ONCOLOGICA

Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer

(2018) Afroz S. Mohammad et al.   PHARMACEUTICAL RESEARCH

A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors

(2016) Nai-Jung Chiang et al.   BMC CANCER

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

(2016) Andrea Wang-Gillam et al.   LANCET

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) M. Ducreux et al.   ANNALS OF ONCOLOGY

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

(2015) T. C. Chang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma

(2015) Michela Capello et al.   JNCI-Journal of the National Cancer Institute

Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma

(2015) Michela Capello et al.   JNCI-Journal of the National Cancer Institute

Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion

(2014) A. V. Kalra et al.   CANCER RESEARCH

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer

(2014) Takuji Okusaka et al.   CANCER SCIENCE

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma†

(2013) A. C. Roy et al.   ANNALS OF ONCOLOGY

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

(2013) A H Ko et al.   BRITISH JOURNAL OF CANCER

FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

(2012) Alberto Zaniboni et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Doxil® — The first FDA-approved nano-drug: Lessons learned

(2012) Yechezkel (Chezy) Barenholz   JOURNAL OF CONTROLLED RELEASE

An overview of the recent progress in irinotecan pharmacogenetics

(2010) Yutaka Fujiwara et al.   PHARMACOGENOMICS

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer

(2009) C Yoo et al.   BRITISH JOURNAL OF CANCER

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients

(2008) E Rouits et al.   BRITISH JOURNAL OF CANCER

Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer

(2008) Seong Yoon Yi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY